Clinical Trials Logo

Multiple Myeloma Progression clinical trials

View clinical trials related to Multiple Myeloma Progression.

Filter by:
  • Not yet recruiting  
  • Page 1

NCT ID: NCT06411301 Not yet recruiting - Clinical trials for Multiple Myeloma in Relapse

A Phase I Study to Assess the Tolerability of 225Ac-DOTATATE in Patients With Refractory and Relapsing Multiple Myeloma Expressing Somatostatin Receptors

AcTRESS
Start date: October 2024
Phase: Phase 1
Study type: Interventional

This study aims to determine the safety and the recommended phase II dose of RYZ101 (actinium-225 labelled DOTA-octreotate (225Ac-DOTATATE)) in participants with refractory and relapsing multiple myeloma (MM) that have received at least 3 prior lines of myeloma therapy. Participants will be selected based on somatostatin receptor (SSTR) positivity assessed by gallium-68 labelled DOTA-octreotate (68Ga-DOTATATE) PET/CT. The response to 225Ac-DOTATATE therapy will also be assessed in the target study population.

NCT ID: NCT03706547 Not yet recruiting - Clinical trials for Multiple Myeloma in Relapse

Anti-CD19/BCMA Bispecific CAR-T Cell Therapy for R/R MM

Start date: October 30, 2018
Phase: Phase 1
Study type: Interventional

The goal of this clinical trial is to study the feasibility and efficacy of anti-CD19/BCMA bispecific chimeric antigen receptors (CARs) T cell therapy for relapsed and refractory multiple myeloma.